Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to -$4.3 million.

  • Medifast's Change in Accured Expenses rose 6164.54% to -$4.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$23.9 million, marking a year-over-year increase of 3166.54%. This contributed to the annual value of -$23.9 million for FY2025, which is 3166.54% up from last year.
  • As of Q4 2025, Medifast's Change in Accured Expenses stood at -$4.3 million, which was up 6164.54% from -$516000.0 recorded in Q3 2025.
  • Medifast's 5-year Change in Accured Expenses high stood at $29.2 million for Q1 2021, and its period low was -$21.9 million during Q1 2023.
  • In the last 5 years, Medifast's Change in Accured Expenses had a median value of -$5.2 million in 2024 and averaged -$3.9 million.
  • In the last 5 years, Medifast's Change in Accured Expenses surged by 158214.29% in 2021 and then crashed by 298214.29% in 2024.
  • Over the past 5 years, Medifast's Change in Accured Expenses (Quarter) stood at $11.6 million in 2021, then plummeted by 231.82% to -$15.3 million in 2022, then skyrocketed by 97.63% to -$364000.0 in 2023, then plummeted by 2982.14% to -$11.2 million in 2024, then surged by 61.65% to -$4.3 million in 2025.
  • Its Change in Accured Expenses stands at -$4.3 million for Q4 2025, versus -$516000.0 for Q3 2025 and -$13.1 million for Q2 2025.